Tofacitinib Ointment For Chronic Plaque Psoriasis
Launched by PFIZER · Apr 10, 2013
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline
- • At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)
- • If received certain treatments, should be off treatment for a minimum period of time (washout)
- Exclusion Criteria:
- • Currently have non-plaque forms of psoriasis or drug-induced psoriasis
- • Require treatment with or cannot stop medication(s) prohibited during the study
- • Have certain laboratory abnormalities at Baseline
- • Current or history of certain infections
- • Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Providence, Rhode Island, United States
Boston, Massachusetts, United States
Johnston, Rhode Island, United States
Hot Springs, Arkansas, United States
Hamilton, Ontario, Canada
Nashville, Tennessee, United States
Houston, Texas, United States
High Point, North Carolina, United States
London, Ontario, Canada
Los Angeles, California, United States
Rapid City, South Dakota, United States
Orange Park, Florida, United States
San Antonio, Texas, United States
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
Montreal, Quebec, Canada
Portland, Oregon, United States
Portland, Oregon, United States
Barrie, Ontario, Canada
Peterborough, Ontario, Canada
Montreal, Quebec, Canada
West Dundee, Illinois, United States
Windsor, Ontario, Canada
Waterloo, Ontario, Canada
Clinton Township, Michigan, United States
Newnan, Georgia, United States
Alpharetta, Georgia, United States
Cincinnati, Ohio, United States
Dallas, Texas, United States
Tampa, Florida, United States
Winston Salem, North Carolina, United States
Greer, South Carolina, United States
Dallas, Texas, United States
Herning, , Denmark
Ajax, Ontario, Canada
San Antonio, Texas, United States
Bakersfield, California, United States
Irvine, California, United States
Atlanta, Georgia, United States
Boston, Massachusetts, United States
Arlington, Texas, United States
Markham, Ontario, Canada
Aarhus C, , Denmark
Warszawa, Mazowieckie, Poland
Poznan, Wielkopolskie, Poland
Bialystok, , Poland
Bialystok, , Poland
Gdansk, , Poland
Krakow, , Poland
Lublin, , Poland
Poznan, , Poland
Warszawa 44, , Poland
Warszawa, , Poland
Wroclaw, , Poland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
